Benjamin Edwards Inc. Purchases 2,741 Shares of STERIS plc $STE

Benjamin Edwards Inc. lifted its position in STERIS plc (NYSE:STE) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,190 shares of the medical equipment provider’s stock after acquiring an additional 2,741 shares during the quarter. Benjamin Edwards Inc. owned 0.14% of STERIS worth $34,696,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of STERIS by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,021 shares of the medical equipment provider’s stock worth $3,178,000 after purchasing an additional 362 shares during the period. NewEdge Advisors LLC raised its stake in STERIS by 3.2% in the first quarter. NewEdge Advisors LLC now owns 6,300 shares of the medical equipment provider’s stock worth $1,428,000 after buying an additional 194 shares in the last quarter. Petrus Trust Company LTA purchased a new stake in STERIS during the first quarter worth $216,000. Jones Financial Companies Lllp boosted its position in STERIS by 46.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 349 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after acquiring an additional 59,264 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Trading Down 0.2%

STERIS stock opened at $259.40 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The stock has a market cap of $25.46 billion, a PE ratio of 37.27 and a beta of 1.03. The stock has a 50-day moving average of $256.61 and a two-hundred day moving average of $245.53. STERIS plc has a one year low of $204.28 and a one year high of $268.60.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same quarter in the prior year, the company posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, research analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Tuesday, November 18th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, November 18th. STERIS’s dividend payout ratio is presently 36.21%.

Insider Buying and Selling

In other news, VP Julia Madsen sold 5,008 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the transaction, the vice president directly owned 10,710 shares of the company’s stock, valued at approximately $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This trade represents a 46.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,044 shares of company stock worth $6,586,218 in the last 90 days. Insiders own 1.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.